Siplizumab

Phase 2Monoclonal antibody

UUniversity of Alabama at Birmingham

Siplizumab is one of 115 biologic programs targeting Lymphoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

114

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

Hidradenitis SuppurativaActive, not recruiting

Sickle Cell DiseaseActive, not recruiting

Renal Transplant Failure and RejectionRecruiting

LymphomaPhase 1

Active, not recruiting

Hidradenitis SuppurativaPhase 1

Active, not recruiting

Sickle Cell DiseasePhase 1/Phase 2

Active, not recruiting

Renal Transplant Failure and RejectionPhase 2

Recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Blenoxane

SSequus Pharmaceuticals

Preclinical

25 2

Siplizumab

UUniversity of Alabama at Birmingham

Phase 2

1 3

Velban

EEastern Cooperative Oncology Group

Preclinical

15 4

Zofran

Novartis

Preclinical

2 5

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 6

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 7

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 8

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—9

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

—10

R-CHOP

IIncyte Biosciences Japan GK

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Recruiting

Hidradenitis Suppurativa

NCT06326476

Q1 2028

Phase 2Recruiting

Renal Transplant Failure and Rejection

NCT07508787

Phase 1Recruiting

ILD

NCT06455280

Q4 2030

Phase 1/2Active, not recruiting

Tolerance

NCT05900401

Clinical

Trials by Indication[1]

Lymphoma1 trial

Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01445535·15 enrolled

T1DM1 trial

Siplizumab in T1DM

Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT05574335·8 enrolled

Hidradenitis Suppurativa1 trial

An Open-label, Time-lagged, Dose-escalation Study to Evalaute the Safety and Efficacy of Subcutaneous Siplizumab in the Treatment of Hidradenitis Suppurativa.

Recruiting·UUniversity of Alabama at Birmingham·Phase 1·NCT06326476·12 enrolled

Sickle Cell Disease1 trial

Siplizumab for Sickle Cell Disease Transplant

Terminated·—·Phase 1/2·NCT06078696·1 enrolled

ILD1 trial

A Study of SIPLIZUMAB in AILD and LT Patients

Recruiting·—·Phase 1·NCT06455280·8 enrolled

2 more indications

Tolerance1 trial

Delayed Tolerance Through Mixed Chimerism

Active, not recruiting·MMassachusetts General Hospital·Phase 1/2·NCT05900401·20 enrolled

Renal Transplant Failure and Rejection1 trial

Phase 2b, Randomized, Multicenter, Double-Blind, Dose-Finding, Active-Controlled Study of Siplizumab (TCD601) Compared to Rabbit Anti-Thymocyte Globulin in Renal Transplant Recipients Requiring Induction Therapy and Receiving Standard of Care Immunosuppression With Tacrolimus, Mycophenolic Acid and Corticosteroids

Recruiting·NNefro Avillion Clinical Development, LLC·Phase 2·NCT07508787·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Siplizumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Siplizumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Siplizumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Alabama at Birmingham company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: UUniversity of Alabama at Birmingham

Siplizumab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q1 2028

Q4 2030

Trials by Indication[1]

Lymphoma1 trial

T1DM1 trial

Hidradenitis Suppurativa1 trial

Sickle Cell Disease1 trial

ILD1 trial

Tolerance1 trial

Renal Transplant Failure and Rejection1 trial

References

Drug Info

Quick Facts

Related News